Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Qiagen ( (QGEN) ).
QIAGEN N.V. has disclosed a managers’ transaction involving board member Stephen H. Rusckowski following the company’s previously announced synthetic share repurchase program. Under the terms of this capital measure, which consolidated every 20 issued QIAGEN shares into 19, Rusckowski’s holdings were adjusted, resulting in a reduction of two shares to a total of 22 common shares, in a transaction executed outside a trading venue and not quantifiable in conventional price-volume terms.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences and diagnostics company whose shares trade in Frankfurt and on several other European exchanges as well as on the NYSE and Swiss markets. The company focuses on sample and assay technologies used in molecular diagnostics, applied testing, academic research and pharmaceutical development.
Average Trading Volume: 1,155,025
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.99B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.